I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject
Sanofi Genzyme

ISPOR-EU 2025 | Nov 9, 2025 - Nov 12, 2025

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, is a neurodegenerative disorder that damages motor neurons. It is characterized by progressive weakness of voluntary muscles that control movement, swallowing, speech, and breathing, which eventually lead to paralysis. In later stages of ALS, cognitive and behavioral impairment may also manifest with death by respiratory failure typically occurring within 3-5 years of onset.

Poster